212 related articles for article (PubMed ID: 30604312)
1. Inhibitor development, safety and efficacy of Advate
Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor development, safety, and efficacy of Advate
Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
[TBL] [Abstract][Full Text] [Related]
3. Perioperative safety and hemostatic efficacy of Advate
Nogami K; Takedani H; Shima M; Yoshioka A; Matsushita T; Takamatsu J; Taki M; Fukutake K; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
Int J Hematol; 2018 Jul; 108(1):22-29. PubMed ID: 29594923
[TBL] [Abstract][Full Text] [Related]
4. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
5. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
[TBL] [Abstract][Full Text] [Related]
7. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K; Shima M; Fukutake K; Fujii T; Taki M; Matsushita T; Higasa S; Sato T; Sakai M; Arai M; Uchikawa H; Engl W; Abbuehl B; Konkle BA
Int J Hematol; 2017 Nov; 106(5):704-710. PubMed ID: 28550352
[TBL] [Abstract][Full Text] [Related]
10. Octocog alfa (Advate®): a guide to its use in hemophilia A.
Keating GM; Dhillon S
BioDrugs; 2012 Aug; 26(4):269-73. PubMed ID: 22759264
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
12. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
[TBL] [Abstract][Full Text] [Related]
15. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
[TBL] [Abstract][Full Text] [Related]
16. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
Dhillon S
Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
[TBL] [Abstract][Full Text] [Related]
17. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
18. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
[TBL] [Abstract][Full Text] [Related]
19. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.
Holstein K; Liu X; Smith A; Knöbl P; Klamroth R; Geisen U; Eichler H; Miesbach W; Tiede A
Blood; 2020 Jul; 136(3):279-287. PubMed ID: 32268359
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Sidonio RF; Thompson AA; Peyvandi F; Stasyshyn O; Yeoh SL; Sosothikul D; Antmen AB; Maggiore C; Engl W; Ewenstein B; Tangada S
Expert Rev Hematol; 2023; 16(10):793-801. PubMed ID: 37646148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
